AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Gilead Sciences Inc
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001S6Y1X7
156.04▼ 1.15 (-0.73%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
157.19
Day's Range
155.76 – 157.65
52-Week Range
114.02 – 160.51
Volume
6.0M
Avg Volume
5.8M
Share Statistics
Shares Outstanding
Employees
17.0K
Exchange
XNAS
Listed
1992-01-22
Share count as of July 31, 2026

Gilead Sciences Inc (GILD) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Gilead Sciences Inc (GILD)
What is Gilead Sciences Inc's Market Cap?
Gilead Sciences Inc's Market Cap is $193.5B, based on as-reported figures from SEC (XBRL) filings.
What is Gilead Sciences Inc's Enterprise Value?
Gilead Sciences Inc's Enterprise Value is $216.5B, based on as-reported figures from SEC (XBRL) filings.
What is Gilead Sciences Inc's Price / Sales?
Gilead Sciences Inc's Price / Sales is 6.4×, based on as-reported figures from SEC (XBRL) filings.
What is Gilead Sciences Inc's EV / Revenue?
Gilead Sciences Inc's EV / Revenue is 7.1×, based on as-reported figures from SEC (XBRL) filings.
What is Gilead Sciences Inc's EV / EBITDA?
Gilead Sciences Inc's EV / EBITDA is 790.3×, based on as-reported figures from SEC (XBRL) filings.
What is Gilead Sciences Inc's Revenue (TTM)?
Gilead Sciences Inc's Revenue (TTM) is $30.5B, based on as-reported figures from SEC (XBRL) filings.
What is Gilead Sciences Inc's Net Income (TTM)?
Gilead Sciences Inc's Net Income (TTM) is -$3.2B, based on as-reported figures from SEC (XBRL) filings.
What is Gilead Sciences Inc's EBITDA?
Gilead Sciences Inc's EBITDA is $274.0M, based on as-reported figures from SEC (XBRL) filings.
What is Gilead Sciences Inc's Diluted EPS (TTM)?
Gilead Sciences Inc's Diluted EPS (TTM) is -2.61, based on as-reported figures from SEC (XBRL) filings.
What is Gilead Sciences Inc's EBITDA Margin?
Gilead Sciences Inc's EBITDA Margin is 0.9%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · GILDAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Total revenues
YoY growth+10.2%+4.4%+4.7%+3.0%
Costs and expenses:
Cost of goods sold
Research and development expenses
Acquired in-process research and development expenses
In-process research and development impairments—
Selling, general and administrative expenses
Total costs and expenses
% of revenue233.2%62.8%75.0%57.2%
Operating (loss) income
% of revenue-133.2%37.2%25.0%42.8%
Interest expense
Other (income) expense, net
(Loss) income before income taxes
Income tax expense
Net (loss) income
% of revenue-134.5%29.0%27.5%39.3%
Basic (loss) earnings per share (in dollars per share)
Diluted (loss) earnings per share (in dollars per share)